비교리스트

 카트 문의
시장보고서
상품코드
1646705

세계의 류마티스 관절염 진단 테스트 시장

Rheumatoid Arthritis Diagnosis Tests
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 441 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

류마티스 관절염 진단 테스트 세계 시장, 2030년까지 10억 달러에 달할 전망

2023년 6억 9,110만 달러로 추정되는 류마티스 관절염 진단 테스트 세계 시장은 2023-2030년 동안 연평균 5.7%의 CAGR로 성장하여 2030년에는 10억 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 혈청학 검사는 CAGR 6.1%를 기록하여 분석 기간 종료 시점에 7억 2,360만 달러에 도달할 것으로 예상되며, RA 치료 효율 모니터링 검사 분야의 성장률은 분석 기간 동안 CAGR 4.9%로 추정됩니다.

미국 시장 1억 8,140만 달러로 추정, 중국은 CAGR 7.4%로 성장 전망

미국의 류마티스 관절염 진단 테스트 시장은 2023년 1억 8,140만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 1억 7,080만 달러의 시장 규모에 도달할 것으로 예상되며, 분석 기간인 2023-2030년 동안 CAGR은 7.4%에 달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 4.2% 및 5.1%의 CAGR을 기록할 것으로 예측됩니다. 유럽에서는 독일이 CAGR 4.6%로 성장할 것으로 예상됩니다.

세계 류마티스 관절염 진단 테스트 시장 - 주요 동향 및 촉진요인 정리

류마티스 관절염 진단 검사란 무엇이며, 왜 필요한가?

류마티스 관절염(RA) 진단 검사는 전 세계 수백만 명이 앓고 있는 이 만성 자가면역질환을 식별하고 관리하기 위한 중요한 도구입니다. 이러한 검사의 주요 목적은 바이오마커, 염증 마커 및 RA 관련 증상을 조기에 발견하여 적시에 치료하고 환자의 예후를 개선할 수 있도록 하는 것입니다. 일반적인 진단 접근법에는 류마티스 인자(RF) 검사, 항고리형 시트룰린화 펩타이드(항CCP) 항체 검사, 적혈구 침강속도(ESR) 검사, C 반응성 단백질(CRP) 검사 등의 혈액 검사와 엑스레이, MRI, 초음파 등의 영상 검사가 있습니다. 이러한 검사들은 RA를 확인하는 것뿐만 아니라 다른 자가면역질환이나 근골격계 질환과의 감별에도 도움이 됩니다. 환자 교육 캠페인과 의사들의 노력으로 조기 진단에 대한 인식이 높아지면서 전 세계적으로 RA 진단 도구의 채택이 확대되고 있습니다.

기술 혁신은 진단의 정확성과 접근성을 어떻게 변화시키고 있는가?

류마티스관절염 진단 분야는 특히 정밀 진단법 개발에서 큰 진전을 보이고 있습니다. 새로운 세대의 바이오마커 기반 분석 및 유전자 검사는 탁월한 정확도를 제공하고 이전 방법을 괴롭혔던 위음성 및 위양성을 감소시키고 있습니다. 현장 진단 키트와 휴대용 기기는 원격지나 의료서비스가 부족한 지역에서 RA를 검사할 수 있게함으로써 접근성을 혁신적으로 개선하고 있습니다. 디지털 이미지와 AI를 활용한 진단 도구는 복잡한 스캔의 해석을 간소화하고 의사에게 데이터에 기반한 인사이트를 실시간으로 제공하고 있습니다. 또한, 현재 진행 중인 분자진단 연구는 질병의 진행을 예측하고 치료 계획을 맞춤화할 수 있는 예측 분석의 길을 열어주고 있습니다. 이러한 발전은 진단 정확도를 향상시킬 뿐만 아니라 RA 진단에 소요되는 시간과 비용을 절감하고 있습니다.

지역별로 RA 진단 검사 수요가 증가하는 이유는?

RA 진단 검사에 대한 수요는 특히 고령화 사회에서의 유병률 증가에 힘입어 전 세계적으로 확대되고 있습니다. 북미와 유럽을 포함한 신흥국 시장에서는 의료 인프라, 보험, 의사들의 인식이 개선되면서 높은 보급률을 보이고 있습니다. 반면, 아시아태평양과 라틴아메리카의 신흥국들은 진단 시설에 대한 접근성 향상과 정부 주도의 의료 개혁으로 인해 빠른 성장을 보이고 있습니다. 또한, 생활습관 관련 염증성 질환의 부담이 증가하고 자가면역질환 관리에 대한 관심이 높아지면서 종합적인 진단 솔루션에 대한 필요성이 증가하고 있습니다. 공중 보건 캠페인과 진단 회사 및 의료 서비스 제공자와의 협력 관계도 RA 진단 도구의 보급에 중요한 역할을 하고 있습니다.

RA 진단 시장의 성장을 이끄는 요인은 무엇일까?

류마티스 관절염 진단 시장의 성장은 진단 도구의 기술 발전, 질병의 조기 발견에 대한 관심 증가, 환자의 인식 증가 등 여러 요인에 의해 주도되고 있습니다. 새로운 바이오마커 기반의 검사 개발, 영상 진단을 위한 AI 및 머신러닝의 발전은 검사의 정확성과 효율성을 높이고 있습니다. 맞춤형 의료에 대한 관심이 높아지면서 RA에 대한 유전자 및 분자 검사의 도입이 촉진되고 있습니다. 또한, RA 및 관련 자가면역질환의 유병률 증가와 신흥 시장에서의 의료 접근성 향상으로 인해 수요가 크게 증가하고 있습니다. 또한, 높아진 인식과 적극적인 건강관리 트렌드에 영향을 받은 소비자 행동도 진단 테스트의 사용 확대에 기여하고 있습니다. 진단 제약회사와 의료 서비스 제공자 간의 전략적 파트너십과 정부 지원책은 시장의 성장 궤도를 더욱 촉진하고 있습니다.

부문

검사 유형(혈청학 검사, RA 치료 효율 모니터링 검사), 최종 용도(진단검사실 최종 용도, 병원 최종 용도, 외래 수술 센터 최종 용도)

조사 대상 기업 사례(주목 66개사)

  • Abbott Core Laboratory
  • Augurex Life Sciences Corp.
  • Beckman Coulter, Inc.
  • Bio Rad Laboratories Inc.
  • Exagen Inc.
  • imaware, Inc.
  • Qiagen NV
  • Roche Diagnostics International AG
  • Siemens Healthcare Private Limited
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.02.14

Global Rheumatoid Arthritis Diagnosis Tests Market to Reach US$1.0 Billion by 2030

The global market for Rheumatoid Arthritis Diagnosis Tests estimated at US$691.1 Million in the year 2023, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2023-2030. Serology Tests, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$723.6 Million by the end of the analysis period. Growth in the Monitoring RA Treatment Efficiency Tests segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$181.4 Million While China is Forecast to Grow at 7.4% CAGR

The Rheumatoid Arthritis Diagnosis Tests market in the U.S. is estimated at US$181.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$170.8 Million by the year 2030 trailing a CAGR of 7.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Rheumatoid Arthritis Diagnosis Tests Market - Key Trends & Drivers Summarized

What Are Rheumatoid Arthritis Diagnosis Tests and Why Are They Essential?

Rheumatoid arthritis (RA) diagnosis tests are critical tools in identifying and managing this chronic autoimmune disorder that affects millions globally. The primary aim of these tests is to detect biomarkers, inflammatory markers, and symptoms associated with RA at an early stage, enabling timely treatment and improved patient outcomes. Common diagnostic approaches include blood tests such as the rheumatoid factor (RF) test, anti-cyclic citrullinated peptide (anti-CCP) antibody test, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) test, alongside imaging techniques like X-rays, MRIs, and ultrasounds. These tests not only confirm RA but also help differentiate it from other autoimmune or musculoskeletal disorders. Increasing awareness about early diagnosis, driven by patient education campaigns and physician initiatives, is broadening the adoption of RA diagnostic tools worldwide.

How Are Innovations Transforming Diagnostic Accuracy and Accessibility?

The field of RA diagnosis has witnessed significant advancements, particularly in the development of precision diagnostics. New-generation biomarker-based assays and genetic tests are offering unparalleled accuracy, reducing false negatives or positives that plagued earlier methods. Point-of-care diagnostic kits and portable devices are revolutionizing accessibility, allowing for RA testing in remote or underserved areas. Digital imaging and AI-driven diagnostic tools are streamlining the interpretation of complex scans, providing physicians with real-time, data-backed insights. Furthermore, ongoing research in molecular diagnostics is paving the way for predictive analytics, enabling healthcare providers to forecast disease progression and customize treatment plans. These advancements are not only enhancing diagnostic precision but are also reducing the time and cost associated with RA identification.

Why Is the Demand for RA Diagnosis Tests Growing Across Geographies?

Demand for RA diagnostic tests is escalating globally, fueled by the rising prevalence of the disease, particularly among aging populations. Developed markets, including North America and Europe, are experiencing high adoption rates owing to better healthcare infrastructure, insurance coverage, and physician awareness. Conversely, emerging economies in Asia-Pacific and Latin America are witnessing rapid growth due to improving access to diagnostic facilities and government-led healthcare reforms. Additionally, the increasing burden of lifestyle-related inflammatory conditions, coupled with the growing focus on autoimmune disease management, is intensifying the need for comprehensive diagnostic solutions. Public health campaigns and collaborations between diagnostic companies and healthcare providers are also playing a pivotal role in expanding the reach of RA diagnosis tools.

What Is Driving the Growth in the RA Diagnosis Market?

The growth in the rheumatoid arthritis diagnosis market is driven by several factors, including technological advancements in diagnostic tools, increased focus on early disease detection, and rising patient awareness. The development of novel biomarker-based tests, along with advancements in AI and machine learning for imaging diagnostics, is enhancing test accuracy and efficiency. A growing emphasis on personalized medicine is encouraging the adoption of genetic and molecular testing for RA. Furthermore, the increasing incidence of RA and related autoimmune disorders, coupled with improved healthcare accessibility in emerging markets, is significantly boosting demand. Consumer behavior, influenced by heightened awareness and proactive health management trends, is also contributing to the expanding use of diagnostic tests. Strategic partnerships between diagnostic companies and healthcare providers, as well as supportive government initiatives, are further propelling the market’s growth trajectory.

SCOPE OF STUDY:

The report analyzes the Rheumatoid Arthritis Diagnosis Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Serology Tests, Monitoring RA Treatment Efficiency Tests); End-Use (Diagnostic Laboratories End-use, Hospitals End-use, Ambulatory Surgical Centers End-use)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 66 Featured) -

  • Abbott Core Laboratory
  • Augurex Life Sciences Corp.
  • Beckman Coulter, Inc.
  • Bio Rad Laboratories Inc.
  • Exagen Inc.
  • imaware, Inc.
  • Qiagen NV
  • Roche Diagnostics International AG
  • Siemens Healthcare Private Limited
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • A Prelude to Rheumatoid Arthritis
    • Diagnostic Tests of Rheumatoid Arthritis
    • Competition
    • EXHIBIT 1: Rheumatoid Arthritis Diagnosis Tests - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Economic Frontiers: Trends, Trials & Transformations
    • EXHIBIT 2: In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
    • EXHIBIT 3: All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
    • EXHIBIT 4: With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
    • Global Market Outlook and Prospects
    • Rheumatoid Arthritis Diagnostic Tests Market in Sprint Mode with Government Support & Spending
    • The US and Europe Dominate the Global Market, Developing Countries to Witness Fastest Growth
    • Anti-Cyclic Citrullinated Peptide (anti-CCP) Tests Projected to Grow Significantly During the Forecast Period
    • Precision Diagnostics & Personalized Medicine as Major Trends
    • Concerns over Low Specificity & Sensitivity to Hinder Growth
    • Recent Market Activity
    • Influencer/Product/Technology Insights
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Rheumatoid Arthritis Propels the Demand for Rheumatoid Arthritis Diagnosis
    • EXHIBIT 5: Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
    • Growing Aging Population to Drive the Demand for RA Diagnostic Tests
    • EXHIBIT 6: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Increasing Use of Rapid Diagnosis Tests Platform
    • Select List of RA Biomarkers used in Clinical Practice
    • Investigational Biomarkers to Diagnose and Monitor RA
    • New Biomarker Tests to Drive the Market Growth
    • Growing Demand for Multiple Tests
    • Repercussions of Sub Optimal Accuracy in RA Testing Drive the Need for Multiple Tests
    • Uptrend in Healthcare Expenditure Drives Opportunities
    • EXHIBIT 7: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Increase in Number of Hospitals & Diagnostics Centers Augurs Well for Market in Developing Regions
    • Increasing Obesity Levels Underpins Market Growth
    • EXHIBIT 8: Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Burgeoning Patient Data Accentuates Worth of AI for Rheumatoid Arthritis Diagnosis
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rheumatoid Arthritis Diagnosis Tests Market Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Serology Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Serology Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Serology Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Monitoring RA Treatment Efficiency Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Monitoring RA Treatment Efficiency Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Monitoring RA Treatment Efficiency Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgical Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Surgical Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ambulatory Surgical Centers End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • Market Analytics
    • TABLE 20: USA Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • TABLE 38: China Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • Market Analytics
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • TABLE 53: France Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • TABLE 71: UK Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • Market Analytics
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • TABLE 110: India Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제